Medtronic is touting its GenCut™ core biopsy system, a unique lung tissue biopsy tool for use with the superDimension™ navigation system which promises decreased biopsy procedure time.
According to the American Lung Association, lung cancer is the leading cause of cancer-related deaths in the United States, one problem being that it presents few, if any symptoms in its early stages. As a result, the vast majority of lung cancer patients are diagnosed in the late stages, when there is minimal chance for long-term survival.
Targeting the need for improved biopsy procedures, Medtronic’s GenCut core biopsy system gained U.S. FDA 510(k) clearance in April 2015.
Pulmonologists and thoracic surgeons can use Medtronic’s superDimension system with which to gain minimally invasive access to the more difficult-to-reach areas of the lung, itself an aid in the diagnosis of lung cancer. The GenCut core biopsy system is a unique tool that allows the operator to collect multiple core samples from lesions deep inside the lungs. With its proprietary blade design, the GenCut core biopsy system can shear and collect larger, more intact samples, according to Medtronic’s in-house data. It allows physicians to provide the pathology laboratory with tissue that enables cytology, histology and molecular profiling for personalized medicine. With the ability to continuously sample, in one pass, physicians can potentially decrease patients’ biopsy procedure times.
“Lung cancer diagnostic clinicians consistently state that tissue is the issue. When performing a biopsy, they need enough tissue for the pathologist to make a diagnosis and to ensure undamaged tissue for genetic testing and molecular analysis. As lung cancer drugs and therapies advance, the ability to provide earlier diagnosis and earlier, personalized treatment can potentially save lives,” said Chuck Brynelsen, president, Early Technologies business in Medtronic’s Minimally Invasive Therapies Group.
He added; “The continuum of care is the healthcare journey a patient takes from diagnosis to recovery. Our goal, across this continuum, is to diagnose earlier, intervene earlier, treat better and help patients recover faster.”
Source: Globe Newswire